Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on OXFORD BIOMEDICA PLC. We currently have 32 research reports from 6 professional analysts.
|22Mar17 07:00||RNS||Holding(s) in Company|
|16Mar17 07:00||RNS||PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2016|
|10Mar17 07:00||RNS||Notice of Preliminary Results|
|01Mar17 10:24||RNS||Total Voting Rights|
|28Feb17 07:00||RNS||Appointment of New Chief Financial Officer|
|24Feb17 09:36||RNS||Director Dealings|
|01Feb17 10:09||RNS||Total Voting Rights|
Frequency of research reports
Research reports on
OXFORD BIOMEDICA PLC
OXFORD BIOMEDICA PLC
Oxford Biomedica - Leading Gene Delivery Platform
23 Mar 17
Oxford BioMedica, a UK-based, clinical stage biotech company, is a global leader in the exciting and rapidly advancing field of gene and cell therapy. They have their own portfolio of pre-clinical and clinical-stage product candidates and also have licensed technology and provide revenue-generating services to third parties, most notably Novartis. Novartis’s CTL019, a breakthrough therapy for leukaemia, may reach the market by year-end.
N+1 Singer - Oxford BioMedica - Full year results; anticipate CTL019 launch later this year
16 Mar 17
Oxford BioMedica’s full year results highlight a step up in bioprocessing and commercial development income following the manufacturing capacity expansion undertaken in 2015 and 2016. However, in the near term the financial outlook continues to look highly dependent on Novartis, which was responsible for the majority of the income increase as Oxford BioMedica supplied the lentiviral vector for CTL019 clinical trials. The group is confident of supplying the vector following regulatory approval of CTL019 for acute lymphoblastic leukaemia (our forecasts currently assume the product is launched in 2017). We remain at Hold.
N+1 Singer - Morning Song 16-03-2017
16 Mar 17
Brady (BRY LN) Building a platform for superior growth and margin | Devro (DVO LN) We see 3 key sentiment drivers for FY17 | EMIS Group (EMIS LN) In line prelims, investment in patient a short term drag | M&C Saatchi (SAA LN) 9.3% LFL revenue growth, 3% profit beat, dividend +15% | Northgate (NTG LN) Strategy refresh expected in June | Oxford BioMedica (OXB LN) Full year results; anticipate CTL019 launch later this year
Hardman & Co Monthly: March 2017
01 Mar 17
Most major pharmaceutical companies have reported results for 2016 during the last few weeks, providing the opportunity to update our industry statistics. For an industry that requires a long investment cycle, decisions made many years ago have consequences on current financial performance. Being able to look at performance over 20 years highlights how strategic decisions have panned out.
N+1 Singer - Oxford BioMedica - Positive CTL019 data
05 Dec 16
The positive CTL019 trial results in ALL (acute lymphoblastic leukaemia) announced by Novartis at the weekend is encouraging. Oxford BioMedica has been manufacturing lentivector material for Novartis since the agreement was first established in 2013. Oxford BioMedica is eligible to royalties on CTL019 product sales. Filing of CTL019 with the FDA remains on track for early 2017. Our forecasts currently assume the product is launched in 2017 and we look forward to additional updates in due course. We remain at Hold.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017